Royal Bank of Canada cut its holdings in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 22.3% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 401,428 shares of the medical research company’s stock after selling 115,491 shares during the period. Royal Bank of Canada’s holdings in IQVIA were worth $68,460,000 at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in the business. Franklin Street Advisors Inc. NC acquired a new stake in shares of IQVIA in the fourth quarter worth approximately $15,724,000. CWM LLC increased its position in IQVIA by 23.9% during the fourth quarter. CWM LLC now owns 55,830 shares of the medical research company’s stock worth $12,585,000 after purchasing an additional 10,762 shares during the last quarter. Calamos Advisors LLC raised its stake in IQVIA by 268.1% during the fourth quarter. Calamos Advisors LLC now owns 188,707 shares of the medical research company’s stock worth $42,536,000 after purchasing an additional 137,441 shares during the period. Assetmark Inc. raised its stake in IQVIA by 33.6% during the fourth quarter. Assetmark Inc. now owns 172,625 shares of the medical research company’s stock worth $38,911,000 after purchasing an additional 43,436 shares during the period. Finally, KBC Group NV boosted its holdings in shares of IQVIA by 68.2% in the 4th quarter. KBC Group NV now owns 779,128 shares of the medical research company’s stock valued at $175,624,000 after purchasing an additional 315,883 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.
Wall Street Analyst Weigh In
IQV has been the subject of a number of research analyst reports. BMO Capital Markets upped their price objective on IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a report on Wednesday. Morgan Stanley reiterated an “equal weight” rating and issued a $200.00 target price (down from $225.00) on shares of IQVIA in a report on Wednesday, June 17th. Barclays reissued an “overweight” rating on shares of IQVIA in a research report on Tuesday. Robert W. Baird raised their price objective on IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a report on Wednesday. Finally, Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research note on Saturday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus target price of $241.88.
IQVIA News Roundup
Here are the key news stories impacting IQVIA this week:
- Positive Sentiment: William Blair upgraded IQVIA to “strong buy,” adding to the favorable analyst outlook. Ticker Report article
- Positive Sentiment: Robert W. Baird raised its IQVIA price target to $287, implying substantial upside from the cited trading level. JPMorgan and Stifel Nicolaus also expressed expectations for further appreciation. American Banking News article on Baird price target American Banking News article on JPMorgan forecast American Banking News article on Stifel outlook
- Positive Sentiment: IQVIA’s second-quarter results exceeded expectations, with adjusted earnings of $3.15 per share versus the $3.03 consensus and revenue of $4.37 billion versus $4.30 billion expected. Revenue increased 8.7% year over year, reinforcing the company’s growth profile. IQVIA Q2 2026 earnings call summary
- Neutral Sentiment: Analysts maintain a “moderate buy” consensus, indicating generally favorable sentiment but not unanimous conviction. IQVIA analyst consensus article
- Negative Sentiment: Two insiders sold shares on July 29: Keriann Cherofsky sold 558 shares for approximately $136,827, while Eric Sherbet sold 5,000 shares for about $1.25 million. Although both retain meaningful holdings, the transactions may create short-term investor concern. SEC insider sale filing for Keriann Cherofsky SEC insider sale filing for Eric Sherbet
IQVIA Stock Performance
Shares of IQV stock opened at $235.09 on Friday. The company has a current ratio of 0.71, a quick ratio of 0.75 and a debt-to-equity ratio of 2.18. The company has a market cap of $38.70 billion, a PE ratio of 29.17, a P/E/G ratio of 1.99 and a beta of 1.20. The company’s fifty day simple moving average is $194.75 and its 200-day simple moving average is $187.20. IQVIA Holdings Inc. has a 52 week low of $154.50 and a 52 week high of $251.36.
IQVIA (NYSE:IQV – Get Free Report) last announced its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. During the same period in the prior year, the company earned $2.81 EPS. The firm’s revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. As a group, equities research analysts anticipate that IQVIA Holdings Inc. will post 11.61 EPS for the current year.
IQVIA declared that its Board of Directors has authorized a stock repurchase plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.
Insider Activity
In related news, insider Eric Sherbet sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the transaction, the insider directly owned 20,999 shares of the company’s stock, valued at approximately $5,232,110.84. The trade was a 19.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Keriann Cherofsky sold 558 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $245.21, for a total value of $136,827.18. Following the completion of the transaction, the insider owned 2,989 shares of the company’s stock, valued at approximately $732,932.69. This represents a 15.73% decrease in their position. The SEC filing for this sale provides additional information. 1.70% of the stock is owned by corporate insiders.
IQVIA Company Profile
IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.
IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.
Featured Stories
- Five stocks we like better than IQVIA
- Popular’s Earnings Beat Shows Why This Bank Stock Keeps Climbing
- ABB’s Rotork Deal Could Put These Flow Control Stocks Back in Focus
- GE HealthCare Stock Climbs on Vital Diagnostics Demand
- Lost in Space: Why Aerospace Valuations Are Plummeting Right Now
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.
